2018
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan D, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. Journal Of Thoracic Oncology 2018, 13: 1248-1268. PMID: 29885479, DOI: 10.1016/j.jtho.2018.05.030.Peer-Reviewed Original ResearchConceptsLiquid biopsyAdvanced non-small cell lungClinical practiceNon-small cell lungResistance mutationsAdvanced NSCLC patientsTumor DNA (ctDNA) assaysCurrent available evidenceCell-free tumor DNALiquid biopsy approachesMultiple cancer typesNSCLC patientsClinical outcomesCell lungLung cancerThoracic oncologyClinical managementMultidisciplinary panelBiopsy approachUnmet needBiopsyPatient careStatement paperTumor DNATumor samples
2004
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC)
Tran H, Zinner R, Blumenschein G, Oh Y, Papadimitrakopoulou V, Kim E, Lu C, Malik M, Lum B, Herbst R. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC). Journal Of Clinical Oncology 2004, 22: 2050-2050. DOI: 10.1200/jco.2004.22.14_suppl.2050.Peer-Reviewed Original ResearchPharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC)
Tran H, Zinner R, Blumenschein G, Oh Y, Papadimitrakopoulou V, Kim E, Lu C, Malik M, Lum B, Herbst R. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC). Journal Of Clinical Oncology 2004, 22: 2050-2050. DOI: 10.1200/jco.2004.22.90140.2050.Peer-Reviewed Original Research